当前位置：
X-MOL 学术
›
Cryst. Growth Des.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Perspectives on the Current State, Challenges, and Opportunities in Pharmaceutical Crystallization Process Development
Crystal Growth & Design ( IF 3.2 ) Pub Date : 2020-11-05 , DOI: 10.1021/acs.cgd.0c00847 Aaron Cote 1 , Deniz Erdemir 2 , Kevin P. Girard 3 , Daniel A. Green 4 , Michael A. Lovette 5 , Eric Sirota 1 , Nandkishor K. Nere 6
Crystal Growth & Design ( IF 3.2 ) Pub Date : 2020-11-05 , DOI: 10.1021/acs.cgd.0c00847 Aaron Cote 1 , Deniz Erdemir 2 , Kevin P. Girard 3 , Daniel A. Green 4 , Michael A. Lovette 5 , Eric Sirota 1 , Nandkishor K. Nere 6
Affiliation
|
Crystallization is the primary process used to purify synthetic drug substances and intermediates as well as to control bulk properties, including particle size, surface area, and flowability. Accordingly, new or improved tools to aid crystallization design are of central importance to drug development. In this Perspective, we provide a brief review of the state of the art, identify current challenges, and highlight key opportunities within different aspects of crystallization process development for synthetic pharmaceutical compounds.
中文翻译：
药物结晶过程发展的现状，挑战和机遇的观点
结晶是提纯合成原料药和中间体以及控制体积特性（包括粒度，表面积和流动性）的主要过程。因此，有助于结晶设计的新的或改进的工具对于药物开发至关重要。在此观点中，我们简要概述了现有技术，确定了当前面临的挑战，并重点介绍了合成药物化合物结晶工艺开发各个方面的关键机遇。
更新日期：2020-12-02
中文翻译：
药物结晶过程发展的现状，挑战和机遇的观点
结晶是提纯合成原料药和中间体以及控制体积特性（包括粒度，表面积和流动性）的主要过程。因此，有助于结晶设计的新的或改进的工具对于药物开发至关重要。在此观点中，我们简要概述了现有技术，确定了当前面临的挑战，并重点介绍了合成药物化合物结晶工艺开发各个方面的关键机遇。
京公网安备 11010802027423号